Wave Neuroscience, Inc. v. PeakLogic, Inc.

District Court, S.D. California·Decided August 13, 2024·No. 3:21-cv-01330·Unknown

Opinion

WAVE NEUROSCIENCE, INC., Case No.: 21cv1330-CAB-SBC

Plaintiff/Counterclaim Defendant, ORDER FOLLOWING INITIAL v. DISCOVERY DISPUTE CONFERENCE PEAKLOGIC, INC., et al.,

Defendants/Counterclaim Plaintiffs. On July 25, 2024, Plaintiff Wave Neuroscience, Inc. (“Plaintiff”) and non-parties Nouvita Medical Management, LLC and Serene Health IPA Medical Corporation (collectively the “Subpoenaed Non-Parties”) lodged a Joint Notice of Discovery Dispute (“Joint Notice”) regarding a dispute arising from subpoenas issued pursuant to Rule 45 of the Federal Rule of Civil Procedure by Plaintiff to the Subpoenaed Non-Parties for the production of documents and deposition testimony. The Court held an on-the-record Initial Discovery Dispute Conference on August 9, 2024. (ECF No. 248.) The Court hereby memorializes the order issued during the August 9, 2024 discovery conference. /// /// This is the latest discovery dispute in this contentious matter in which numerous discovery disputes have necessitated court intervention. The discovery period has been extended on multiple occasions and the parties have engaged in extensive document production. Plaintiff presently seeks additional documents, as well as depositions, from non-parties. On July 9 and 10, 2024,1 Plaintiff served subpoenas commanding the production of documents and deposition testimony from the Subpoenaed Non-Parties, who are Defendant PeakLogic’s licensees, regarding the following: (1) communications regarding Plaintiff, this action, and the asserted patents; (2) agreements with Defendants PeakLogic, Inc. and Kevin T. Murphy, M.D. (“Defendants”) and any payments made; (3) training materials and information received from Defendants for use in testing or treating patients and the PeakLogic TMS treatment method; (4) services provided to other clinics licensing the PeakLogic system; (5) treatment plans from Defendants for five patients who completed a full treatment plan of at least five treatments (and corresponding pre- and post-treatment EEGs), and the implementation or modification of those treatment plans; (6) marketing materials; and (7) summary or statistical information relating to use of Defendants’ products and services (reports received from Defendants, outcome of treatments administered, conditions/disorders treated, and number of TMS devices maintained and treatments performed per device). (Joint Notice at 1-2.) The subpoenas set forth a document production date of July 24, 2024, and deposition dates of July 29 and 30, 2024. (Id. at 2.) The Subpoenaed Non-Parties objected to the subpoenas on multiple bases, for example contending that the subpoenas created an undue

1 The Joint Notice indicates that the subject subpoenas were issued in “early July 2024.” (Joint Notice at 2.) In response to the Court’s questioning at the discovery burden, and refused to produce any documents or appear for depositions. (Id. at 5-6.) With respect to the burden, the Subpoenaed Non-Parties assert: [T]he expense to the Non-Parties to produce the requested patient information is enormous and would require many hours of rushed, collective effort on behalf of the Non-Parties, most of whom are small businesses and individual practices and who do not have the financial resources or support staff in place to undertake such an onerous task.

Free access — add to your briefcase to read the full text and ask questions with AI

Wave Neuroscience, Inc. v. PeakLogic, Inc., (S.D. Cal. 2024).

Wave Neuroscience, Inc. v. PeakLogic, Inc. (Wave Neuroscience, Inc. v. PeakLogic, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Linder, David v. Calero-Portocarrero
251 F.3d 178 (D.C. Circuit, 2001)
Stormans Inc v. Mary Selecky
738 F.3d 1178 (Ninth Circuit, 2013)